Where does Enable Injections, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Enable Injections, Inc. ranks #13,969 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Enable Injections, Inc. hold?

Enable Injections, Inc. holds 21 US utility patents granted between 2018 and 2025, spanning 7 technology areas.

What is Enable Injections, Inc.'s Innovation Score?

Enable Injections, Inc. has an Innovation Score of 39.7 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Enable Injections, Inc.'s patent grant rate increasing or decreasing?

Enable Injections, Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Enable Injections, Inc.'s patents?

Enable Injections, Inc.'s patents average 13.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Enable Injections, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Enable Injections, Inc.

Q: What technology areas does Enable Injections, Inc. focus on?

Enable Injections, Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 18 patents, ranking #413 of 3,490 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 21 granted patents across 7 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Enable ranks #13,969 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 7 technology areas.

#13,969
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.7/100): 13.7
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13969 · US Corporation #13,969 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,969/49,997
PHOTO-FINISH Emboline
CPC-NARROW A61M · 7 areas
INNOV-THIN 39.7/100
CLAIMS-RICH 13.7 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Emboline, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Enable’s 39.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (27%) Velocity 11.4 pts (29%) Breadth 9.4 pts (24%) Claim depth 8.2 pts (21%)

Qualcomm Incorporated · highest

85
Enable Injections · this assignee

40
3D Lighting… · lowest

7

What this shows Enable's Innovation Score is 39.7/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Enable?

Each dot is one of Enable’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Enable’s own 13.7 claims/patent is at or below the 14.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Enable vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Enable's grants concentrate

Enable Injections, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 85.7% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2023 (6 grants) versus a trough of 1 in 2018. By volume, Enable sits between Emboline, Inc. and EtaGen, Inc..

Enable's three-year grant acceleration

Enable Injections, Inc. shows 12 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Emboline

21
Embry-riddle Aero…

21
Emerson Climate (…

21
Enpower

21
Energy Full

21
Epivax

21
Erber

21
Etagen

21
Enable Injections ◀

21

What this shows Enable holds 21 patents at rank #13,973, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Enable

By rank, the assignees closest to #13,973 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Enable's primary technology class.

Enable's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Enable Injections, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	4.8%
2019	3	14.3%
2020	1	4.8%
2021	3	14.3%
2022	3	14.3%
2023	6	28.6%
2024	3	14.3%
2025partial year	1	4.8%

Which technologies does Enable Injections, Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 18

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 9

A61B - DIAGNOSIS; SURGERY; Identification 3

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 2

F04B - Positive-displacement Machines FOR LIQUIDS; Pumps 2

F16K - VALVES; TAPS; COCKS; ACTUATING-FLOATS; Devices FOR Venting OR Aerating 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Enable Injections, Inc.'s patent record in context - here's where to go next.

Enable Injections, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 85.7% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #13,969 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Enable Injections, Inc. against Emboline, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.